Nuplazid Safety Review: Blast From the Past Or Preview Of Future Terrors?
Executive Summary
Fueled by Congress, media attention, reevaluation of Acadia's Parkinson's drug feels like a scandal from pharma's primary care era – but is also a glimpse of what things might look like for industry if Democrats retake the House.
You may also be interested in...
Acadia Claims Success For Nuplazid In A Broader Psychosis Indication
The company expects to file pimavanserin for the treatment of dementia-related psychosis in 2020, based on the results of a single positive Phase III trial.
Finance Watch: Moderna Launches Biggest Biopharma IPO Ever As US Market Resets Expectations
Public Company Edition: Moderna's $604m IPO launches as the US stock market is in decline and public biotechs are doing especially poorly. Also, as Shire acquisition closing moves near, Takeda firms up additional financing; and Global Blood, Theravance, Amarin capitalize on good news.
Keeping Track: An Approval For Ajovy, A CRL For Ruconest, And Some Submissions from J&J
The latest drug development news and highlights from our US FDA Performance Tracker.